United States Lipid Nanoparticle Market Report by Type, Application, End Use, States and Company Analysis, 2026-2034

United States Lipid Nanoparticle Market: Future Outlook, Growth Trends & Forecast (2026–2034)

United States Lipid Nanoparticle Market is expected to reach US$ 574.01 Billion by 2034 from US$ 232.56 Billion in 2025, with a CAGR of 10.56% from 2026 to 2034. The expanding use of lipid nanoparticles for mRNA delivery, gene therapy, vaccines, and precision medicines is driving market growth in the United States. Advances in targeted delivery, formulation science, and scalable manufacturing are further encouraging pharmaceutical and biotechnology companies to adopt LNP platforms.

United States Lipid Nanoparticle Industry Landscape

Lipid nanoparticles are microscopic delivery systems made primarily from specialized lipids that encapsulate and transport biological molecules into cells. They can protect fragile payloads such as messenger RNA, small interfering RNA, DNA, and other nucleic acids from degradation while facilitating cellular uptake. LNPs generally contain ionizable lipids, phospholipids, cholesterol, and stabilizing components that work together to influence particle formation, circulation, cellular entry, and payload release. Their adaptable structure enables researchers to modify formulations for different therapeutic purposes. Consequently, lipid nanoparticles have become an important technology for vaccines, gene therapies, RNA medicines, cancer applications, and emerging precision-delivery approaches across pharmaceutical and biotechnology research.

The growing development of RNA-based and genetic medicines is creating strong demand for lipid nanoparticles in the United States. LNPs provide an adaptable mechanism for transporting nucleic-acid payloads while improving their stability and facilitating intracellular delivery. Pharmaceutical developers are increasingly investigating customized formulations capable of directing therapeutic molecules toward specific tissues and cell types. Progress in ionizable lipid chemistry, particle engineering, microfluidic formulation, and analytical characterization is broadening the potential applications of LNP technology. At the same time, collaborations between biotechnology companies, academic institutions, contract development organizations, and specialized technology providers are strengthening the domestic ecosystem and supporting faster movement from laboratory research toward clinical development and manufacturing.

Recent Breakthroughs Shaping the United States Lipid Nanoparticle Industry

• In July 2026, Galmed Pharmaceuticals announced the development of a novel lipid nanoparticle formulation of Aramchol in collaboration with Barcode Nanotech. The formulation is designed to redirect the drug's biodistribution from liver cells toward cardiac tissue, demonstrating the growing focus on organ-specific LNP delivery. The development highlights how LNP engineering is moving beyond conventional hepatic delivery toward targeted applications for cardiovascular diseases and other difficult-to-reach tissues.
• In November 2025, ReCode Therapeutics initiated enrollment in a Phase 2 clinical study involving its proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform. The platform is designed to deliver genetic medicines with greater precision to specific organs, supporting the industry's shift toward tissue-selective non-viral delivery. The clinical progression demonstrates the increasing movement of advanced LNP technologies from preclinical research toward human therapeutic development.

Major Growth Drivers Shaping the Future of United States Lipid Nanoparticle Sector

1. RNA Therapeutics Expand the LNP Opportunity

The expanding pipeline of RNA-based medicines is positioning lipid nanoparticles as an important enabling technology for the U.S. biopharmaceutical industry. Researchers are exploring LNP systems for mRNA, siRNA, gene-editing components, and other nucleic-acid payloads, creating demand for delivery platforms that can improve stability, cellular uptake, and therapeutic performance. Increasingly sophisticated formulations are also being designed to influence tissue distribution and release characteristics. This shift is encouraging specialized companies to develop improved lipids, formulation technologies, screening platforms, and characterization tools. The emergence of targeted LNP approaches could further expand applications beyond established vaccine uses into oncology, metabolic disorders, cardiovascular conditions, neurological diseases, and rare disorders.

In September 2025, Oxford Nanoimaging (ONI) announced the launch of its LNP Sample Characterization Service in San Diego, California, providing researchers with high-resolution analysis of LNP size, cargo loading, ligand positivity, stability, and aggregation.

2. Advances in Targeted and Tissue-Specific Delivery

The development of targeted lipid nanoparticles is opening new possibilities for delivering genetic medicines to previously difficult-to-reach tissues. Researchers are increasingly moving beyond conventional formulations toward systems engineered to interact with particular cell populations or biological barriers. Such advances could improve therapeutic precision while potentially reducing unwanted exposure to other tissues. Interest is particularly strong in applications involving the brain, immune system, liver, tumors, and other specialized biological environments. Research organizations and biotechnology companies are consequently investing in novel ionizable lipids, targeting ligands, particle architectures, and screening technologies. These developments are strengthening the role of LNPs as a flexible platform for next-generation therapeutics.

In February 2025, researchers at the Icahn School of Medicine at Mount Sinai in New York reported a blood-brain-barrier-crossing LNP platform capable of delivering mRNA to the brain following systemic administration, highlighting opportunities for neurological applications.

Mount Sinai press release – Brain-Targeting LNP Platform

3. Growing Investment in Scalable LNP Manufacturing

The commercialization of advanced medicines is increasing the importance of reproducible and scalable lipid nanoparticle manufacturing. Developers require reliable processes that can transition from early formulation research to preclinical studies, clinical production, and eventually commercial manufacturing. This is stimulating innovation in microfluidic mixing, process control, formulation optimization, analytical testing, and automated production. Specialized technology suppliers are also introducing systems that allow researchers to produce nanoparticles with greater consistency and flexibility. As pharmaceutical companies pursue increasingly complex nucleic-acid therapies, demand is shifting toward integrated development capabilities that combine formulation, characterization, process development, and manufacturing support.

In April 2025, MEPSGEN announced the U.S. launch of NanoCalibur™, a microfluidic nanoparticle production platform designed for laboratory-scale and preclinical applications, including LNP production.

Critical Challenges Facing the United States Lipid Nanoparticle Industry

1. Formulation Complexity and Manufacturing Consistency

Lipid nanoparticle development involves multiple formulation variables that can influence particle size, encapsulation, stability, cellular uptake, biodistribution, and payload release. Small changes in lipid composition, mixing conditions, or processing parameters may affect product characteristics. Maintaining consistency as a formulation moves from laboratory development to larger-scale manufacturing can therefore be challenging. Developers also require sophisticated analytical capabilities to characterize nanoparticles and monitor critical quality attributes. These requirements can increase development complexity and demand specialized expertise. Establishing robust processes that remain reproducible across batches and manufacturing environments is consequently an important challenge for companies seeking to commercialize LNP-based products.

2. Safety, Targeting and Regulatory Complexity

Although LNPs offer significant delivery advantages, their biological interactions can create challenges related to tolerability, immune responses, biodistribution, and repeated administration. Formulations designed for one therapeutic application may not perform similarly in another tissue or patient population. Researchers therefore need extensive preclinical evaluation to understand how different lipid compositions behave in the body. Targeted delivery adds another layer of complexity because improving localization while limiting unintended exposure requires careful formulation and biological optimization. Developers must also establish strong evidence around manufacturing quality, product consistency, safety, and therapeutic performance. These considerations can lengthen development programs and increase the technical requirements associated with advanced LNP therapeutics.

California – The West Coast Engine of LNP Innovation

California represents a dynamic environment for lipid nanoparticle development because of its concentration of biotechnology companies, research universities, venture-backed life-science businesses, and advanced therapeutic programs. The state supports research spanning RNA medicines, gene therapy, regenerative medicine, oncology, and cardiovascular applications, creating multiple pathways for LNP adoption. Academic laboratories and biotechnology developers are investigating new lipid compositions, targeted delivery strategies, and therapeutic payloads. California also benefits from specialized analytical and manufacturing capabilities that can support the transition from discovery toward clinical development. Collaboration between universities, startups, technology suppliers, and pharmaceutical companies is helping create an innovation ecosystem where lipid nanoparticles can be tested across diverse therapeutic applications and delivery challenges.

Texas – Building a Therapeutic Delivery Powerhouse

Texas is developing an increasingly active ecosystem for lipid nanoparticle and non-viral delivery research, supported by biotechnology companies, medical research institutions, and pharmaceutical development organizations. The state's growing life-science infrastructure creates opportunities for LNP applications in gene therapy, RNA therapeutics, metabolic diseases, oncology, and other areas requiring intracellular delivery. Companies are exploring lipid formulations that can improve endosomal escape, tissue specificity, and therapeutic payload performance. The presence of specialized research and manufacturing capabilities also supports collaborations between emerging biotechnology businesses and established industry participants. As developers seek alternatives to viral delivery systems, Texas is positioned to contribute to the advancement of scalable non-viral platforms and next-generation genetic medicine technologies.

Dallas-based Signify Bio launched in June 2025 with its iPhos platform, a lipid nanoparticle delivery system designed to support nucleic-acid-enabled protein therapeutics and improve endosomal escape and tissue specificity.

New York – Precision Delivery Meets Biomedical Research

New York provides a strong foundation for lipid nanoparticle research through its major medical institutions, universities, biotechnology organizations, and translational research programs. Researchers are investigating LNPs for challenging delivery environments, including the central nervous system, where conventional delivery approaches face significant biological barriers. The state's research ecosystem encourages collaboration between clinicians, biomedical engineers, pharmaceutical developers, and academic scientists. Such interactions support experimentation with targeted nanoparticles, novel lipid materials, RNA payloads, and disease-specific delivery strategies. New York's strong concentration of biomedical research also creates opportunities for LNP technologies to move from laboratory discoveries toward translational and therapeutic applications, particularly in neurology, oncology, gene therapy, and precision medicine.

In February 2025, Mount Sinai researchers in New York reported a blood-brain-barrier-crossing LNP system for systemic mRNA delivery to the brain.

Florida – Advancing Translational Nanomedicine

Florida's expanding biotechnology and medical research landscape is creating opportunities for lipid nanoparticle applications in drug delivery, vaccines, gene therapy, and precision medicine. Universities, research centers, hospitals, and emerging biotechnology companies are contributing to translational research that connects nanoparticle engineering with therapeutic development. LNP technology can complement research programs focused on RNA medicines and other biological payloads that require efficient intracellular delivery. The state's growing healthcare innovation environment also supports collaboration among academic researchers, clinicians, and pharmaceutical organizations. Continued development of specialized laboratories, biotechnology infrastructure, and research partnerships could strengthen Florida's role in the broader U.S. LNP ecosystem while supporting new approaches to therapeutic delivery.

United States Liposomes Market

The United States liposomes market is supported by the broad use of lipid-based vesicles in pharmaceutical delivery, diagnostics, research, and specialized therapeutic formulations. Liposomes can encapsulate hydrophilic and hydrophobic compounds, helping developers modify drug distribution, stability, and release characteristics. Their established role in drug-delivery research provides an important foundation for continued innovation in nanomedicine. Pharmaceutical and biotechnology companies are exploring liposomal formulations for oncology, infectious diseases, pain management, and other therapeutic areas where controlled delivery may improve treatment performance. Advances in lipid chemistry, formulation engineering, surface modification, and analytical characterization are also encouraging the development of more sophisticated liposomal systems. Increasing integration with precision medicine may further expand their application across the U.S. healthcare ecosystem.

United States Therapeutics Lipid Nanoparticle Market

The United States therapeutics lipid nanoparticle market is developing rapidly as pharmaceutical companies investigate LNPs for delivering RNA and other genetic payloads. Therapeutic applications extend beyond vaccines toward gene silencing, gene editing, protein replacement, cancer treatment, metabolic disorders, cardiovascular conditions, and neurological diseases. Developers are increasingly focusing on tissue-selective formulations that can transport therapeutic molecules beyond conventional delivery sites. Innovation in ionizable lipids, targeting ligands, particle composition, and manufacturing processes is helping improve the flexibility of LNP platforms. Partnerships between pharmaceutical companies, biotechnology firms, academic institutions, and specialized delivery technology providers are also supporting therapeutic development. Continued progress in safety, repeat dosing, biodistribution, and manufacturing could broaden the clinical utility of LNP-based medicines.

United States Academic & Research Institutes Lipid Nanoparticle Market

Academic and research institutes represent an important component of the U.S. lipid nanoparticle ecosystem because they provide fundamental research, formulation innovation, biological evaluation, and early-stage therapeutic discovery. Universities and medical research centers are investigating new lipid materials, targeted delivery mechanisms, tissue-specific nanoparticles, and novel nucleic-acid payloads. Research programs increasingly combine nanotechnology with molecular biology, immunology, oncology, neuroscience, and gene therapy. These institutions also provide a pipeline of scientific talent and intellectual property that can be transferred to biotechnology companies through partnerships and commercialization programs. Government-supported research further encourages exploration of difficult delivery challenges, including crossing biological barriers and improving intracellular transport. As academic discoveries mature, collaboration with industry can accelerate translation toward clinical applications.

Research Methodology of the United States Lipid Nanoparticle Market

The United States Lipid Nanoparticle Market was estimated using a structured bottom-up and top-down market-sizing methodology, supported by secondary research, product-level revenue analysis, application-based demand assessment, pharmaceutical pipeline evaluation, pricing analysis, company-level revenue estimation, and data triangulation. The methodology considered lipid nanoparticles (LNPs) used in drug delivery, messenger RNA (mRNA) vaccines, gene therapies, nucleic acid therapeutics, and other biomedical applications. The assessment focused on the United States market and evaluated demand from pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), research institutions, and other end users.

1. Market Definition and Scope

• The market was first defined by establishing the scope of lipid nanoparticles used for pharmaceutical, therapeutic, vaccine development, and biomedical research applications in the United States.
• The assessment covered lipid nanoparticle formulations, associated lipid components, formulation technologies, and related development and manufacturing services where applicable.
• The scope was aligned with the revenue generated from lipid nanoparticle products and services within the United States, while avoiding double counting between lipid raw materials, formulated nanoparticles, and outsourced manufacturing services.

2. Secondary Research and Data Collection

• Extensive secondary research was conducted to collect information on the United States lipid nanoparticle industry from reliable sources.
• Data was gathered from the U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), clinical trial registries, scientific publications, patent databases, company annual reports, investor presentations, product catalogs, and official company websites.
• Information regarding lipid nanoparticle technologies, clinical development programs, product approvals, manufacturing capabilities, research investments, and commercial partnerships was reviewed.
• Company disclosures and product documentation were analyzed to identify lipid nanoparticle suppliers, specialized lipid manufacturers, formulation technology developers, and contract manufacturing providers operating in the United States.
• Research publications and clinical trial records were examined to understand the adoption of lipid nanoparticles in mRNA delivery, gene therapy, oncology, infectious disease vaccines, and other therapeutic applications.
• The collected information was organized by product category, application, end user, and revenue-generating activity to establish the market's underlying structure.

3. Identification of Key Market Participants

• Companies operating across the lipid nanoparticle value chain were identified, including manufacturers of ionizable lipids, specialty lipid ingredients, formulated LNP systems, and related delivery technologies.
• Pharmaceutical companies, biotechnology developers, and CDMOs involved in lipid nanoparticle formulation, scale-up, and commercial manufacturing were evaluated.
• Company-level information was collected on product portfolios, manufacturing facilities, research and development activities, strategic partnerships, licensing agreements, and customer segments.
• Publicly available financial disclosures were reviewed to identify relevant revenue streams associated with lipid nanoparticle products and services.
• For companies reporting combined revenues from multiple lipid technologies or broader pharmaceutical ingredients, the portion attributable to lipid nanoparticles was estimated using product-level disclosures, portfolio composition, manufacturing capabilities, and other relevant secondary information.
• Companies were classified according to their principal market role to reduce duplication across raw material suppliers, formulation providers, and service companies.

4. Lipid Nanoparticle Product and Technology Analysis

• The market was assessed by identifying the major lipid components and formulation technologies used in lipid nanoparticle development.
• Ionizable lipids were evaluated because of their importance in facilitating the delivery of nucleic acids into target cells.
• Phospholipids, cholesterol, and PEGylated lipids were assessed based on their roles in nanoparticle structure, stability, circulation characteristics, and formulation performance.
• Information on proprietary lipid technologies, formulation platforms, encapsulation methods, and manufacturing processes was collected from company publications, patents, scientific literature, and product documentation.
• Commercially available lipid ingredients and specialized formulation products were distinguished from experimental technologies used primarily in preclinical or academic research.
• The analysis also considered differences between research-grade materials, clinical-grade formulations, and products manufactured for commercial pharmaceutical applications.
• Product-level demand and revenue estimates were developed based on the commercial availability, therapeutic relevance, and adoption of each technology.

5. Application-Based Demand Assessment

• Demand for lipid nanoparticles was assessed across the principal therapeutic and research applications in the United States.
• The mRNA vaccine segment was evaluated by examining the use of LNP delivery systems in approved vaccines, vaccine development programs, and emerging infectious disease research.
• Gene therapy and nucleic acid delivery applications were assessed by reviewing the development of LNP-based systems for delivering messenger RNA, small interfering RNA (siRNA), and other nucleic acid payloads.
• Drug delivery applications were evaluated by examining the use of lipid nanoparticles in oncology, genetic disorders, and other therapeutic areas.
• Research and preclinical applications were assessed through academic publications, biotechnology research programs, laboratory procurement activities, and publicly disclosed research partnerships.
• Clinical trial databases and company pipeline disclosures were used to identify development-stage programs that could contribute to future demand.
• Application-level demand was estimated by considering the number of active programs, development stage, formulation requirements, expected manufacturing volumes, and commercial adoption potential.

6. Market Estimation Using the Bottom-Up Approach

• The bottom-up approach was used to estimate the United States lipid nanoparticle market by aggregating revenues associated with individual products, lipid components, formulations, and relevant services.
• Product-level sales, disclosed contract values, manufacturing activity, and estimated annual demand were analyzed wherever reliable secondary information was available.
• For products with identifiable sales volumes, annual revenue was calculated using estimated units sold and average selling prices.
• For customized LNP formulations and manufacturing services, revenue was estimated using disclosed service pricing, production capacity, customer demand, and relevant contract information.
• Where companies did not disclose product-specific revenue, estimates were developed by allocating relevant business revenue to lipid nanoparticle activities based on product portfolios and operational disclosures.

• Formulas used:

• Product-Level Revenue = Units Sold × Average Selling Price
• Lipid Component Revenue = Estimated Quantity Sold × Average Selling Price per Unit
• LNP Formulation Revenue = Formulations Supplied × Average Price per Formulation
• LNP Manufacturing Service Revenue = Manufacturing Projects × Average Revenue per Project
• Company-Level LNP Revenue = Sum of Relevant LNP Product and Service Revenues
• Bottom-Up Market Size = Sum of Estimated Revenues of All Relevant Market Participants

7. Market Estimation Using the Top-Down Approach

• The top-down approach was used to validate the market estimate by examining the broader pharmaceutical delivery systems, specialty lipid ingredients, nucleic acid therapeutics, and relevant drug delivery markets.
• Publicly available market information and company financial disclosures were reviewed to identify the portion of these broader categories attributable to lipid nanoparticle technologies.
• The analysis considered the contribution of LNP-based vaccines, RNA therapeutics, gene delivery applications, and outsourced formulation and manufacturing activities.
• Revenue allocations were adjusted to exclude unrelated lipid products, non-LNP delivery technologies, and activities outside the United States.
• Estimates were refined using the commercialization status of relevant therapies, the adoption of LNP delivery platforms, and the proportion of pharmaceutical development programs using these systems.
• The resulting estimate was compared with the bottom-up calculation to assess consistency and identify possible gaps in market coverage.

• Formulas used:

• Relevant Market Revenue = Total Relevant Market Revenue × Estimated LNP Contribution Percentage
• United States LNP Revenue = Relevant Global LNP Revenue × Estimated United States Share
• Top-Down Market Size = Sum of Estimated United States Revenue Across Relevant LNP Applications

8. Pricing and Revenue Analysis

• Pricing analysis was conducted to estimate the average selling prices of lipid components, formulated lipid nanoparticles, and related development and manufacturing services.
• Available price information was collected from supplier catalogs, product quotations published by vendors, procurement records where accessible, company disclosures, and commercial agreements.
• Differences in prices were assessed according to lipid composition, formulation complexity, purity requirements, production scale, quality standards, and intended application.
• Research-grade lipid materials were distinguished from clinical-grade and commercial manufacturing inputs because of differences in specifications and production requirements.
• For custom LNP formulation and CDMO services, pricing was evaluated according to batch size, development complexity, analytical testing, scale-up requirements, and manufacturing scope.
• Where actual transaction prices were unavailable, average selling prices were estimated using comparable products and documented commercial information.

• Formulas used:

• Average Selling Price (ASP) = Total Product Revenue ÷ Total Units Sold
• Estimated Product Revenue = Estimated Sales Volume × Estimated ASP
• Annual Manufacturing Revenue = Number of Batches Produced × Average Revenue per Batch
• Price-Adjusted Market Value = Estimated Sales Volume × Applicable Average Selling Price

9. Clinical Pipeline and Commercialization Assessment

• The clinical pipeline was evaluated to understand the potential future demand for lipid nanoparticle technologies in the United States.
• Clinical trial registries, company pipelines, scientific publications, and regulatory announcements were reviewed to identify LNP-based vaccines, RNA therapeutics, and gene delivery candidates.
• Programs were categorized by development stage, therapeutic indication, sponsor, delivery technology, and expected manufacturing requirements.
• Approved products and commercially established applications were distinguished from preclinical and clinical-stage candidates.
• Potential demand from pipeline programs was assessed based on development progress, anticipated clinical trial requirements, manufacturing scale, and commercialization prospects.
• The analysis accounted for the uncertainty associated with clinical failures, regulatory delays, and changes in development strategies.
• Pipeline activity was primarily used to validate market drivers and inform future market projections rather than treating every candidate as current commercial revenue.

10. End-User and Procurement Analysis

• Demand was evaluated across pharmaceutical companies, biotechnology firms, CDMOs, academic institutions, and research organizations operating in the United States.
• Pharmaceutical and biotechnology companies were assessed based on their use of LNP technologies in drug development, clinical trials, vaccine production, and therapeutic commercialization.
• CDMOs were evaluated based on their lipid formulation, encapsulation, analytical testing, process development, and large-scale manufacturing capabilities.
• Academic and research institutions were assessed through published research, funded projects, laboratory procurement activities, and collaborations with biotechnology companies.
• End-user demand estimates were developed by considering the number of relevant development programs, estimated consumption of lipid materials, outsourced manufacturing requirements, and commercial production volumes.
• Differences between research demand and commercial pharmaceutical demand were considered to ensure that market estimates reflected the appropriate revenue-generating activities.

11. Historical Market Analysis and Forecasting

• Historical market performance was assessed using available company disclosures, product launches, regulatory approvals, manufacturing expansions, research investments, and adoption trends.
• The relationship between LNP technology development, mRNA therapeutic commercialization, clinical pipeline growth, and manufacturing capacity was evaluated.
• Forecast assumptions were developed based on expected demand from nucleic acid therapeutics, vaccine development, gene delivery research, and the expansion of specialized manufacturing capabilities.
• Future market revenue was projected by considering changes in product adoption, pricing, production volumes, technology development, and the commercialization of relevant therapies.
• Potential constraints, including manufacturing complexity, raw material availability, formulation stability, regulatory requirements, and high development costs, were incorporated into the forecasting assumptions.
• Different growth scenarios were considered where uncertainty surrounding clinical development, commercial adoption, and manufacturing capacity could materially influence future market performance.

12. Data Triangulation and Final Market Validation

• The bottom-up and top-down estimates were compared to identify differences in revenue coverage, application allocation, company contributions, and geographic scope.
• Product-level estimates were cross-checked against company disclosures, supplier information, manufacturing capacity, commercial agreements, and available market benchmarks.
• Potential double counting between lipid ingredient sales, finished LNP formulations, and outsourced manufacturing services was reviewed and adjusted.
• Revenues from unrelated lipid products, non-LNP delivery technologies, and activities outside the United States were excluded.
• Historical growth patterns, clinical pipeline developments, regulatory milestones, and observed commercial activity were used to validate the assumptions.
• Estimates based on incomplete company disclosures or limited price information were reviewed against comparable products and other reliable secondary sources.
• The final market size was established after reconciling the estimates, validating the principal assumptions, and ensuring consistency across product categories, applications, end users, and the United States geographic boundary.

Market Segmentations

Type

• Liposomes
• Nanostructured Carriers
• Solid Lipid Nanoparticles
• Others

Application

• Therapeutics
• Research

End Use

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Merck KGaA
• Evonik Industries AG
• Genevant Sciences Corporation
• CordenPharma
• Arcturus Therapeutics, Inc.
• Ascendia Pharmaceuticals
• Acuitas Therapeutics
• Croda International Plc.

Report Details: